Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access August 9, 2011

Continuous subcutaneous insulin infusion vs. multiple daily injections

  • Saša Radenković EMAIL logo , Milica Pešić , Milena Velojić Golubović , Dragan Dimić , Danijela Radojković , Vojislav Ćirić and Radivoj Kocić
From the journal Open Medicine

Abstract

[1] The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986 http://dx.doi.org/10.1056/NEJM19930930329140110.1056/NEJM199309303291401Search in Google Scholar

[2] UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998;352:837–853 http://dx.doi.org/10.1016/S0140-6736(98)07019-610.1016/S0140-6736(98)07019-6Search in Google Scholar

[3] Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001;358:739–746 http://dx.doi.org/10.1016/S0140-6736(01)05842-110.1016/S0140-6736(01)05842-1Search in Google Scholar

[4] Pickup J, Keen H. Continuous subcutaneous insulin infusion 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002;25:593–598 http://dx.doi.org/10.2337/diacare.25.3.59310.2337/diacare.25.3.593Search in Google Scholar PubMed

[5] Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:705–708 http://dx.doi.org/10.1136/bmj.324.7339.70510.1136/bmj.324.7339.705Search in Google Scholar PubMed PubMed Central

[6] Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L: Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000;23:583–588 http://dx.doi.org/10.2337/diacare.23.5.58310.2337/diacare.23.5.583Search in Google Scholar PubMed

[7] Zinman B: Insulin pump therapy and rapid acting insulin: what have we learned? Int J Clin Pract 2001;123:47–50 Search in Google Scholar

[8] Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med 2006;23:285–292 http://dx.doi.org/10.1111/j.1464-5491.2005.01781.x10.1111/j.1464-5491.2005.01781.xSearch in Google Scholar PubMed

[9] Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004;21:1213–1220 http://dx.doi.org/10.1111/j.1464-5491.2004.01323.x10.1111/j.1464-5491.2004.01323.xSearch in Google Scholar PubMed

[10] Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, et al. Comparison of a multiple daily insulin injection regimen (basal oncedaily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009;32:1170–1176 http://dx.doi.org/10.2337/dc08-187410.2337/dc08-1874Search in Google Scholar PubMed PubMed Central

[11] Harmel AP, Mathur R. Similar A1C outcomes in type 1 diabetic patients undergoing intensive diabetes management with preprandial rapid-acting insulin and either CSII or glargine. Diabetes Care 2004;27:272–273 http://dx.doi.org/10.2337/diacare.27.1.272-a10.2337/diacare.27.1.272-aSearch in Google Scholar PubMed

[12] Davidson P, Hebblewhite H, Steed R, Bode B. A deductive framework to aid in understanding CSII parameters: carbohydrate-to-insulin ratio (CIR) and correction factor (CF). Program and abstracts of the 63rd Scientific Sessions of the American Diabetes Association; June 13–17, 2003; New Orleans, Louisiana. Abstract 443-P Search in Google Scholar

[13] Hannaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber J. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. Diabetes Care 2000;23:1232–1235 http://dx.doi.org/10.2337/diacare.23.9.123210.2337/diacare.23.9.1232Search in Google Scholar PubMed

[14] Doyle EA, Weinzimer SA, Steffen AT, Ahern JAH, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004;27:1554–1558 http://dx.doi.org/10.2337/diacare.27.7.155410.2337/diacare.27.7.1554Search in Google Scholar PubMed

[15] Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008;31Suppl 2:S140–S145 http://dx.doi.org/10.2337/dc08-s23510.2337/dc08-s235Search in Google Scholar PubMed

[16] Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabetic Medicine 2008;25:765–774 http://dx.doi.org/10.1111/j.1464-5491.2008.02486.x10.1111/j.1464-5491.2008.02486.xSearch in Google Scholar PubMed

[17] Retnakaran R, Hochman J, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V, et al. Continuous subcutaneous insulin infusion versus multiple daily injections: The impact of baseline A1c. Diabetes Care 2004:27:2590–2596 http://dx.doi.org/10.2337/diacare.27.11.259010.2337/diacare.27.11.2590Search in Google Scholar PubMed

[18] Nimri R, Weintrob N, Benzaquen H, Ofan R, Fayman G, Phillip M. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. Pediatrics 2006;117:2126–2131 http://dx.doi.org/10.1542/peds.2005-262110.1542/peds.2005-2621Search in Google Scholar PubMed

[19] Fahlén M, Eliasson B, Oden A. Optimization of basal insulin delivery in type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine. Diabetic Medicine 2005;22:382–386 http://dx.doi.org/10.1111/j.1464-5491.2004.01444.x10.1111/j.1464-5491.2004.01444.xSearch in Google Scholar PubMed

[20] Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003;26:1079–1087 http://dx.doi.org/10.2337/diacare.26.4.107910.2337/diacare.26.4.1079Search in Google Scholar PubMed

[21] Karagianni P, Sampanis Ch, Katsoulis Ch, Miserlis G, Polyzos S, Zografou I, et al. Continuous subcutaneous insulin infusion versus multiple daily injections. Hippokratia 2009;13:93–96 Search in Google Scholar

[22] Weintrob N, Benzaquen H, Galatzer A, Shalitin S, Lazar L, Fayman G, et al. Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Regimens in Children with Type 1 Diabetes: A Randomized Open Crossover Trial. Pediatrics 2003;112:559–564 http://dx.doi.org/10.1542/peds.112.3.55910.1542/peds.112.3.559Search in Google Scholar PubMed

[23] The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001;24:1711–1721 http://dx.doi.org/10.2337/diacare.24.10.171110.2337/diacare.24.10.1711Search in Google Scholar PubMed PubMed Central

Published Online: 2011-8-9
Published in Print: 2011-10-1

© 2011 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 1.3.2024 from https://www.degruyter.com/document/doi/10.2478/s11536-011-0064-7/html
Scroll to top button